Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Octreotide
Drug ID BADD_D02412
Description Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction.[L14501] In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may also occur. Acromegaly is a life-threatening disease requiring life-long management.[L14501] Octreotide is a long-acting drug with pharmacologic activities that mimic those of the natural hormone, somatostatin, which inhibits the secretion of growth hormone.[L14513] Additionally, it is used for the treatment of acromegaly and symptoms arising from various tumors, including carcinoid tumors and vasoactive intestinal tumors (VIPomas).[L14513] In the past, octreotide has been administered solely by injection. On June 26, 2020, the first approved delayed-release oral somatostatin analog, Mycapssa, received FDA approval for the long term maintenance treatment of acromegaly. This drug was developed by Chiasma Inc.[L14495,L14507,L14528]
Indications and Usage For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Marketing Status Not Available
ATC Code H01CB02
DrugBank ID DB00104
KEGG ID D00442
MeSH ID D015282
PubChem ID 448601
TTD Drug ID D02XIY
NDC Product Code 62147-0206; 35207-0002; 52416-118; 41524-0007; 52416-109; 69880-120
Synonyms Octreotide | SMS 201-995 | SMS 201 995 | SMS 201995 | SM 201-995 | SM 201 995 | SM 201995 | Sandoz 201-995 | Sandoz 201 995 | Sandoz 201995 | Compound 201-995 | Compound 201 995 | Compound 201995 | SAN 201-995 | SAN 201 995 | SAN 201995 | Octreotide Acetate | Octreotide Acetate Salt | Sandostatine | Sandostatin
Chemical Information
Molecular Formula C49H66N10O10S2
CAS Registry Number 79517-01-4
SMILES CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4= CC=CC=C4)NC(=O)C(CC5=CC=CC=C5)N)C(=O)NC(CO)C(C)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Skin discolouration23.03.03.0050.005881%Not Available
Skin disorder23.03.03.0070.003921%Not Available
Skin lesion23.03.03.0100.003921%Not Available
Sleep disorder19.02.04.0010.007841%Not Available
Small intestinal obstruction07.13.06.0010.005881%
Somnolence19.02.05.003; 17.02.04.006--
Speech disorder22.02.05.034; 19.19.02.002; 17.02.08.0030.003921%Not Available
Steatorrhoea07.17.01.0020.003921%Not Available
Stomatitis07.05.06.005--
Stress19.06.02.0040.027444%Not Available
Swelling08.01.03.0150.005881%Not Available
Swelling face23.04.01.018; 10.01.05.0180.007841%Not Available
Syncope02.01.02.008; 24.06.02.012; 17.02.04.0080.017642%
Tachycardia02.03.02.0070.013722%Not Available
Tearfulness19.15.02.0050.003921%Not Available
Thirst14.03.02.007; 08.01.09.0210.007841%Not Available
Thrombosis24.01.01.0060.011762%Not Available
Transient ischaemic attack24.04.06.005; 17.08.04.0010.007841%
Tremor17.01.06.0020.013722%
Tricuspid valve incompetence02.07.05.0010.003921%Not Available
Ulcer08.03.06.0010.003921%Not Available
Urinary incontinence17.05.01.008; 20.02.02.0100.005881%
Urinary tract infection20.08.02.001; 11.01.14.0040.025483%
Urticaria23.04.02.001; 10.01.06.001--
Vaginal haemorrhage21.08.01.001; 24.07.03.0050.003921%
Varicose vein24.10.04.0010.003921%Not Available
Vertigo17.02.12.002; 04.04.01.0030.007841%
Viral infection11.05.04.0010.005881%Not Available
Viral upper respiratory tract infection22.07.02.004; 11.05.04.0070.003921%Not Available
Vision blurred17.17.01.010; 06.02.06.0070.007841%
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 13 Pages